On January 10, 2022, Scopus BioPharma Inc. announced the final voting results on each of the proposals, as reported by First Coast. According to the final results the shareholders elected Morris C. Laster's nominees as Class A directors on the Board to serve until the 2024 annual meeting of stockholders.